Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fampridine sustained release - Acorda Therapeutics

Next Previous
Drug Profile

Fampridine sustained release - Acorda Therapeutics

Alternative Names: 4-AP - Acorda Therapeutics; Ampyra; BIIB 041; Dalfampridine ER; Dalfampridine extended-release; Dalfampridine-SR; EL 970; Fampridine ER; Fampridine extended-release; Fampridine-PR; Fampridine-SR; Fampyra; Neurelan

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elan Drug Technologies
  • Developer Acorda Therapeutics; Biogen; John Hopkins University; Kessler Foundation; University of California at Los Angeles; University of Florida; University of Miami
  • Class Aminopyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Ataxia
  • Phase II Spinal cord injuries; Spinocerebellar degeneration
  • Phase I/II Parkinson's disease
  • No development reported Cerebral palsy
  • Discontinued Neurological disorders; Transverse myelitis

Most Recent Events

  • 02 Apr 2024 Merz Pharmaceuticals enters into an asset purchase agreement with Acorda Therapeutics to acquire Inbrija and Amprya
  • 11 Jan 2024 Acorda anticipates termination of its licensing agreement with Biogen for fampridine sustained release in Africa, Asia, Australasia, Europe, Far-East, Middle-East in January 2025
  • 24 Mar 2022 Biogen plans to launch fampridine sustained release for Multiple sclerosis in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top